{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T12:16:47Z","timestamp":1771589807052,"version":"3.50.1"},"reference-count":29,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2022,1,28]],"date-time":"2022-01-28T00:00:00Z","timestamp":1643328000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["P30\u2010AR\u2010070155"],"award-info":[{"award-number":["P30\u2010AR\u2010070155"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["K24\u2010AR\u20100074534"],"award-info":[{"award-number":["K24\u2010AR\u20100074534"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000069","name":"NIAMS","doi-asserted-by":"publisher","award":["5T32-AR-007304-40"],"award-info":[{"award-number":["5T32-AR-007304-40"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["acrjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Arthritis Care &amp; Research"],"published-print":{"date-parts":[[2022,3]]},"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>Sarcoidosis is often treated with glucocorticoids, although the use of biologics is growing. Prescribing patterns for biologics for patients with sarcoidosis in US rheumatology practices have never been examined. Given that there are no steroid\u2010sparing US Food and Drug Administration\u2013approved therapies for sarcoidosis, we sought to characterize the real\u2010world treatment of sarcoidosis and to assess practice\u2010level variation in prescribing patterns.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We conducted an observational study of patients with sarcoidosis using data from the Rheumatology Informatics System for Effectiveness (RISE) registry (2014\u20132018). The RISE registry represents an estimated 32% of the US clinical rheumatology workforce. Adult patients with \u22652 codes for sarcoidosis \u226530\u2009days apart were included. We examined sarcoidosis\u2010specific medication use at any time during the study period. Data were analyzed at the practice level.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 3,276 patients with sarcoidosis from 184 practices were included. Of those patients, 75.1% were women, with a mean age of 59.0\u2009\u00b1\u200912.5\u2009years; 48.3% were White and 27.6% were Black. Overall, 59.3% of patients were prescribed glucocorticoids, and 24.7% received prolonged glucocorticoid therapy (\u226510 mg\/day for \u226590\u2009days). In all, 12.1% received a biologic or targeted synthetic disease\u2010modifying antirheumatic drug (tsDMARD), most commonly tumor necrosis factor inhibitors. There was wide practice\u2010level variation among 31 practices with \u226530 patients with sarcoidosis; biologic use ranged from 15.6% to 69.2%. Infliximab represented the most common biologic prescribed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>In a large sample of US rheumatology practices, 12.1% of patients with sarcoidosis received biologics or tsDMARDs. We found high variability in biologic use across practices. The significant use of long\u2010term glucocorticoids suggests unmet therapeutic needs in this patient population.<\/jats:p><\/jats:sec>","DOI":"10.1002\/acr.24496","type":"journal-article","created":{"date-parts":[[2020,10,26]],"date-time":"2020-10-26T14:38:52Z","timestamp":1603723132000},"page":"371-376","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Treatment of Sarcoidosis in <scp>US<\/scp> Rheumatology Practices: Data From the American College of Rheumatology's Rheumatology Informatics System for Effectiveness (<scp>RISE<\/scp>) Registry"],"prefix":"10.1002","volume":"74","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7754-5581","authenticated-orcid":false,"given":"Nevin","family":"Hammam","sequence":"first","affiliation":[{"name":"University of California  San Francisco"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Evans","sequence":"additional","affiliation":[{"name":"University of California  San Francisco"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8235-1781","authenticated-orcid":false,"given":"Esi","family":"Morgan","sequence":"additional","affiliation":[{"name":"University of Cincinnati  Cincinnati Ohio"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Reimold","sequence":"additional","affiliation":[{"name":"Dallas Veterans Affairs Medical Center and University of Texas Southwestern University Medical Center  Dallas Texas"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Anastasiou","sequence":"additional","affiliation":[{"name":"University of California  San Francisco"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia L.","family":"Kay","sequence":"additional","affiliation":[{"name":"University of California  San Francisco"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3508-4094","authenticated-orcid":false,"given":"Jinoos","family":"Yazdany","sequence":"additional","affiliation":[{"name":"University of California  San Francisco"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2687-5043","authenticated-orcid":false,"given":"Gabriela","family":"Schmajuk","sequence":"additional","affiliation":[{"name":"University of California, San Francisco and San Francisco Veterans Affairs Medical Center  San Francisco California"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2022,1,28]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01819-2016"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccm.2015.08.013"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2011.10"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1080\/17512433.2018.1486706"},{"key":"e_1_2_6_6_1","first-page":"325","article-title":"Current and emerging pharmacological treatments for sarcoidosis: a review","volume":"7","author":"Beegle SH","year":"2013","journal-title":"Drug Des Devel Ther"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1513\/AnnalsATS.201511-760OC"},{"key":"e_1_2_6_8_1","first-page":"1261","article-title":"High\u2010cost sarcoidosis patients in the United States: patient characteristics and patterns of health care resource utilization","volume":"23","author":"Rice JB","year":"2017","journal-title":"J Manag Care Spec Pharm"},{"key":"e_1_2_6_9_1","first-page":"119","article-title":"The clinical course of sarcoidosis: presentation, diagnosis, and treatment in a large white and black cohort in the United States","volume":"29","author":"Judson MA","year":"2012","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.23089"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00408-017-0054-x"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/0895-4356(92)90133-8"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1097\/CPM.0000000000000136"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2015.10.024"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1136\/thx.2006.062836"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1097\/MIB.0b013e31828133fd"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-019-2092-7"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.2147\/TCRM.S74476"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00051907"},{"key":"e_1_2_6_20_1","first-page":"124","article-title":"A new side of sarcoidosis: medication and hospitalization use in a privately insured patient population","volume":"36","author":"Low D","year":"2019","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2009.12.009"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00000914"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3181ec7ff9"},{"key":"e_1_2_6_24_1","first-page":"1613","article-title":"Rituximab for refractory granulomatous eye disease","volume":"6","author":"Lower EE","year":"2012","journal-title":"Clin Ophthalmol"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1805958"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr2.11112"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.05.098"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0189599"},{"key":"e_1_2_6_29_1","first-page":"1866","article-title":"Practice\u2010level variation in quality of care in the ACR's Rheumatology Informatics System for Effectiveness (RISE) registry. Arthritis","volume":"68","author":"Yazdany J","year":"2016","journal-title":"Rheumatol"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2018.10.005"}],"container-title":["Arthritis Care &amp; Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/acr.24496","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/acr.24496","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/acr.24496","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T17:43:44Z","timestamp":1759427024000},"score":1,"resource":{"primary":{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/10.1002\/acr.24496"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,28]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["10.1002\/acr.24496"],"URL":"https:\/\/doi.org\/10.1002\/acr.24496","archive":["Portico"],"relation":{},"ISSN":["2151-464X","2151-4658"],"issn-type":[{"value":"2151-464X","type":"print"},{"value":"2151-4658","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,28]]},"assertion":[{"value":"2020-04-06","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-10-22","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-01-28","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}